Company Research Report: Resolve Stroke

Company Overview

• Company Name: Resolve Stroke

• Mission: Transforming Ultrasound data into life-saving diagnostics to impact millions of lives worldwide.

• Founded: 2022

• Founders:

• Aritz Zamacola, CEO

• Vincent Hingot, CTO

• Olivier Couture, Scientific Director

• Key People:

• Séverine Devignevielle, Clinical & Regulatory Director

• Maxime Rault, VP Engineering

• Maxence Reberol, Lead Software Engineer

• Headquarters: Paris Santé Cochin, Hôpital Cochin, 29 Rue du Faubourg Saint-Jacques, 75014 Paris, France

• Number of Employees: 11-50

• Revenue: No information is available

• Known For: Innovating in medical diagnostics with software-defined ultrasound technologies focusing on brain imaging and neurocritical care.

Products

• RS Neuro Suite

• Description: Advanced ultrasound software integrated into the SYLVER platform, designed to expand diagnostics access and support precision treatments.

• Key Features:

• Accessible, non-invasive, compact, and user-friendly.

• Provides reliable quantitative insights into cerebral blood flow and perfusion.

• Supports brain imaging for neurology, intensive care, and emergency medicine.

• SYLVER Platform

• Description: An autonomous ultrasound scanner for neurocritical care, integrating RS Neuro Suite.

• Key Features:

• Upgradeable software-based platform, ensuring adaptability to technological advancements.

• Portable and practical for bedside use, providing comprehensive imaging in under two minutes.

• Accessible for use by clinicians without extensive ultrasonography expertise.

• Biomarkers under Development:

• RS USP: Delayed ischemic risk score for identifying patients at high risk of brain damage following severe neurological injury.

• RS LVO: Arterial permeability index for evaluating brain blood supply and detecting blockages.

• Stealth Scores: Emerging biomarkers to enhance healthcare diagnostics for brain applications.

Recent Developments

• Clinical Trials: Initiated a groundbreaking trial using the SYLVER platform to evaluate transcranial ultrasound data for detecting cerebral hypoperfusion in neurocritical care units.

• Events:

• Presented advancements and clinical results at JFR 2024 and engaged in industry collaborations.

• Participated in the RSNA 2023 meeting in Chicago.

• Collaborations: Engaged with clinical partners, including CHU Caen Normandie, to pioneer neurocritical care research.

• Awards & Recognition:

• Won the Prix Innovation at JFR 2023 for the startup category.

• Selected as a finalist for the Spinoff 2023 award by Springer Nature.

• Investments: Raised €2.2 million in seed funding led by OVNI Capital and Quantonation.

• Partnerships: Collaborating with industry leaders, hospitals, and healthcare associations to drive ultrasound diagnostics innovation.

• Events & Networking: Participated in significant events like NVIDIA’s healthcare computing applications event and hosted by Orsi Academy.

This professional research report provides a detailed overview of Resolve Stroke's mission, product offerings, and recent strategic advancements that illustrate their impact in transforming medical diagnostics through ultrasound technology.